Funding
The raise is open to qualified institutional and family office investors. Capital is concentrated, milestone-driven and structured for downside protection — the same discipline we ask of every founder we back.
The majority of the raise funds initial positions in a deliberately small number of companies working on metabolic health, brain longevity and human performance.
A meaningful reserve is held back to support the companies that prove out — following our winners rather than spreading thin across the whole portfolio.
Capital is set aside for independent clinical validation, scientific review and technical diligence, so claims are tested before they are underwritten.
Fund operations, audit, independent administration and investor reporting are funded as core infrastructure, not as an afterthought.
For investors
For founders
We lead or co-lead early positions where the underlying biology is credible and the team can execute against a defined milestone.
Capital is structured to fund the next hard evidence point — a study readout, a device validation, a regulatory step — not an open-ended runway.
Companies that clear their milestone gain access to reserves, downstream co-investors and operating support across science, regulatory and commercial.
Next step
Economics, allocation policy and lifecycle detail are shared with qualified investors under the final offering documents. All terms are indicative until then.